TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of “Hold” from Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have received a consensus recommendation of “Hold” from the seven brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $6.60.

Several analysts recently weighed in on TCRX shares. Needham & Company LLC decreased their price target on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley downgraded shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. BTIG Research cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 4th. Finally, HC Wainwright reduced their price objective on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp purchased 75,500 shares of TScan Therapeutics stock in a transaction dated Monday, December 22nd. The shares were purchased at an average cost of $0.90 per share, for a total transaction of $67,950.00. Following the completion of the acquisition, the insider owned 8,012,916 shares in the company, valued at $7,211,624.40. This represents a 0.95% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders purchased 161,801 shares of company stock valued at $145,621 in the last quarter. Corporate insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds have recently bought and sold shares of TCRX. Hsbc Holdings PLC purchased a new stake in shares of TScan Therapeutics during the first quarter valued at $49,000. Checkpoint Capital L.P. lifted its holdings in TScan Therapeutics by 14.9% during the 1st quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock valued at $2,784,000 after buying an additional 261,663 shares in the last quarter. BVF Inc. IL lifted its holdings in TScan Therapeutics by 63.6% during the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock valued at $6,747,000 after buying an additional 1,900,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in TScan Therapeutics by 6.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after buying an additional 9,676 shares during the period. Finally, Deutsche Bank AG grew its stake in TScan Therapeutics by 149.4% in the 1st quarter. Deutsche Bank AG now owns 52,559 shares of the company’s stock worth $73,000 after acquiring an additional 31,481 shares in the last quarter. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Stock Performance

TCRX opened at $1.03 on Wednesday. The firm has a market cap of $58.45 million, a P/E ratio of -0.92 and a beta of 1.03. TScan Therapeutics has a 12 month low of $0.88 and a 12 month high of $3.21. The company has a current ratio of 6.44, a quick ratio of 6.44 and a debt-to-equity ratio of 0.23. The stock has a 50-day moving average of $1.21 and a 200 day moving average of $1.60.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The business had revenue of $2.51 million for the quarter, compared to the consensus estimate of $1.98 million. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%. As a group, research analysts forecast that TScan Therapeutics will post -1.12 EPS for the current year.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.